Frailty is a mortality risk factor in tafamidis-treated patients with transthyretin cardiac amyloidosis.

Vyndaqel (tafamidis meglumine) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42721369

Amaury Broussier; Amira Zaroui; Charlotte Lafont; Emmanuel Teiger; Jean-Philippe David; Marie Laurent; Mounira Kharoubi; Nathalie Marie-Nelly; Nina Liu; Silvia Oghina; Sylvie Bastuji Garin; Thibaud Damy

Sep 11, 2026